Eszol Use In Pregnancy & Lactation

Pregnancy: Eszol must not be used during pregnancy except for life-threatening cases where the potential benefit to the mother outweighs the potential harm to the foetus see Contraindications.
In animal studies itraconazole has shown reproduction toxicity see Contraindications.
There is limited information on the use of Eszol during pregnancy. During post-marketing experience, cases of congenital abnormalities have been reported. These cases included skeletal, genitourinary tract, cardiovascular and ophthalmic malformations as well as chromosomal and multiple malformations. A causal relationship with itraconazole has not been established.
Epidemiological data on exposure to itraconazole during the first trimester of pregnancy-mostly in patients receiving short-term treatment for vulvovaginal candidosis-did not show an increased risk for malformations as compared to control subjects not exposed to any known teratogens.
Women of child bearing potential: Women of childbearing potential taking Eszol should use contraceptive precautions. Effective contraception should be continued until the next menstrual period following the end of Eszol therapy..
Lactation: A very small amount of itraconazole is excreted in human milk. The expected benefits of Eszol therapy should be weighed against the risks of breast feeding. In case of doubt, the patient should not breast feed.